Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies.

Soeiro, Maria de Nazaré C; Dantas, Andréia P; Daliry, Anissa; Silva, Cristiane F da; Batista, Denise G J; de Souza, Elen M; Oliveira, Gabriel M; Salomão, Kelly; Batista, Marcos Meuser; Pacheco, Michelle G O; Silva, Patrícia Bernardino da; Santa-Rita, Ricardo M; Barreto, Rubem F S Menna; Boykin, David W; Castro, Solange Lisboa de.
Mem Inst Oswaldo Cruz; 104 Suppl 1: 301-10, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19753489
Chagas disease, which is caused by the intracellular parasite Trypanosoma cruzi, is a neglected illness with 12-14 million reported cases in endemic geographic regions of Latin America. While the disease still represents an important public health problem in these affected areas, the available therapy, which was introduced more than four decades ago, is far from ideal due to its substantial toxicity, its limited effects on different parasite stocks, and its poor activity during the chronic phase of the disease. For the past 15 years, our group, in collaboration with research groups focused on medicinal chemistry, has been working on experimental chemotherapies for Chagas disease, investigating the biological activity, toxicity, selectivity and cellular targets of different classes of compounds on T. cruzi. In this report, we present an overview of these in vitro and in vivo studies, focusing on the most promising classes of compounds with the aim of contributing to the current knowledge of the treatment of Chagas disease and aiding in the development of a new arsenal of candidates with anti-T. cruzi efficacy.
Selo DaSilva